GTx, Inc. (NASDAQ: GTXI) is likely to have an incredibly strong day in the market today, and for good reason. The company reported clinical findings that proved to be overwhelmingly positive. As a result, when investors start to catch on to the news, we’re expecting to see strong gains. Today, we’ll talk about the news and what we’ll be watching for with regard to GTXI ahead.
GTXI Reports Strong Clinical Data
As mentioned above, GTx is likely to have a strong day in the market today after reporting positive data. In a press release issued minutes ago, the company announced additional results from its Phase 2 proof-of-concept clinical trial surrounding 3 mg enobosarm administered orally. The treatment was designed by GTXI for postmenopausal women with stress urinary incontinence, also known as SUI.
The data that was released largely surrounded MRI results from patients’ pelvic floor muscle. In the release, the company said that new data in a subset of women also suggest a positive treatment effect of enobosarm for urge incontinence, or UI. As a result, enobosarm may prove to be a treatment for women with mixed incontinence.
In the release, GTXI said that the results from a pre-specified analysis of MRI data demonstrate a significant increase in pelvic floor muscle thickness as well as eurethral muscle diameter. Also, the company said that the treatment reduced mean UI episodes by around 68% in patients who experienced UI as well as SUI, based on a post hoc analysis of a subset of women with both UI and SUI. In a statement, Kenneth M. Peters, M.D., Chairman of Urology at the Oakland University William Beaumont School of Medicine, and the principal investigator in the GTx trial. Here’s what he had to offer:
Enobosarm’s overall treatment effect was consistent with previously announced trials, and importantly, these new results demonstrate that enobosarm may address a broader treatment need since many women suffer from symptoms of both stress and urge incontinence, also known as mixed incontinence… In addition, with the MRI results, we are seeing anatomical changes supporting enobosarm’s mechanism of action on pelvic floor muscle.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on GTXI. In particular, we’re interested in following the ongoing development of enobosarm as the treatment seems to be yielding incredibly positive results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!